Accelerate to discover

Back to filter

Related topics

Webinar recording: Autofluorescence management - the power of Spectral Flow Cytometry

Cytek Biosciences

Jul 15, 2021

One of the key advantages of spectral flow cytometry is its ability to extract sample autofluorescence, making it much...

Webinar recording: Super-Resolution imaging of Chromatin organization in health and disease

ONI

Jul 6, 2021

Understanding how cells organize the array of components within their membranous confines can not only provide insight...

Jul 31, 2021

PMOD Virtual User Meeting

Bruker Biospin

Jun 7, 2021

We look forward to welcoming many of our users to 2021 PMOD User Meeting. The theme of our PMOD User Meeting will be...

IncuCyte webinar recording: How to measure Immune Cell Killing of Tumor Cells effectively

Sartorius & Essen BioScience

Jun 4, 2021

Immuno-oncology (IO) has transformed cancer treatment. The number of treatments in the IO pipeline continues to...

Jul 31, 2021

Bruker webinar: Experiences in The Use of Micro-CT in Insect Research

Bruker Biospin

Jun 3, 2021

High resolution micro-CT is being used routinely in science. Mostly it is being used as a substitute to microscopy to...

Show all topics (10)

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

Aug 21, 2017

September 7, 2017, 7 pm CEST

Chia-Wei Li, PhD, The University of Texas M. D. Anderson Cancer Center 

Here we reveal PD-L1’s immunosuppression activity is stringently modulated by the spatial restraints between ubiquitination and N-linked glycosylation. We identified GSK3beta as a novel PD-L1 interacting protein capable of inducing phosphorylation dependent proteasome degradation. The essence of PD-L1 N192, N200 and N219 glycosylation suggests it antagonizes GSK3beta binding. In this regard, only non-glycosylated PD-L1 forms a complex with GSK3beta and beta-TrCP. More importantly, activation of GSK3beta-mediated PD-L1 degradation by TKI can reduce membrane PD-L1 expression and thereby enhance anti-tumor immunity. To test T cell-mediated cancer cell killing in vitro, we employed a time lapse microscopy, IncuCyte, to monitor RFP-tagged BT549 cells and activated PBMC interaction over a five day period. Massive cancer cell death was observed in glycosylation deficient cancer cells, suggesting glycosylation of PD-L1 is required for its immunosuppression. Together, our results link ubiquitination and glycosylation pathways with stringent regulation of PD-L1, proposing a new therapeutic strategy to enhance cancer immune therapy efficacy.

Learning objectives:

  • Molecular mechanism of PD-L1 regulation in cancer cells
  • Immunosuppressive nature of triple negative breast cancer
  • Using in vitro co-culture system to analyze T cell-mediated cancer cell killing effect

Register now

Webinar

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

Sartorius & Essen BioScience

Essen BioScience & Sartorius is a team of engineers and biologists with deep expertise in cell-based assays and biomolecular interaction analysis. They invent, manufacture, supply and support instrumentation, reagents and protocols.

Related products

High throughput, real-time and automated measurements of live-cell activity, inside your incubator

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey